In 2023, a performance-based sponsorship agreement produced an unhedgeable liability.

There was no regulated instrument to transfer that risk — only exposure. That exposure materialized.

Vitruvitas was founded on a single conviction: that performance-linked risk belongs in regulated markets, not on balance sheets.